SLC12A2 and ischemia: These studies demonstrated effective improvement of ischemic stroke-induced memory deficits by bumetanide at a low dose (0.3–0.5 mg/kg, once daily ip) likely involving non-NKCC1 mechanisms in models of carotid artery stenosis (Yu et al., 2018) and neonate hypoxia (Wang et al., 2015), but higher doses of 7–40 mg/kg were needed for efficacy in the MCAO ischemia model (O'Donnell et al., 2004) (Table 2).